Erratum: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
Lyon A. R., Lopez-Fernandez T., Couch L. S., Asteggiano R., Aznar M. C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D. J., de Azambuja E., de Boer R. A., Dent S. F., Farmakis D., Gevaert S. A., Gorog D. A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S. S., Stephens R., Suter T. M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C. G., van der Meer P., van der Pal H. J. H.
Abstract
In Figure 7, the category 'Very high risk' has been corrected online to 'High and very high risk'
Topics & Concepts
MedicineInternal medicineClinical OncologyOncologyMedical physicsCancerChemotherapy-induced cardiotoxicity and mitigationLung Cancer Diagnosis and TreatmentCardiac tumors and thrombi